Jacy Barker, APRN
Psychiatric/Mental Health · Wichita, KSNPI 1407281272
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 584 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 584 payments — averaging $15.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$979
- Vanda Pharmaceuticals Inc.$875
- Neurocrine Biosciences, Inc.$808
- Alkermes, Inc.$796
- plus $3K from 16 others
What the payments were for
- Food & beverage$8,98199%
- Education$471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 104 | $1,406 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $1,231 |
| Teva Pharmaceuticals USA, Inc. | 52 | $979 |
| Vanda Pharmaceuticals Inc. | 44 | $875 |
| Neurocrine Biosciences, Inc. | 55 | $808 |
| Alkermes, Inc. | 47 | $796 |
| Johnson & Johnson | 55 | $695 |
| AbbVie | 51 | $600 |
| Lundbeck LLC | 29 | $448 |
| Indivior Inc. | 21 | $303 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $280 |
| Sunovion Pharmaceuticals Inc. | 12 | $161 |
| Axsome Therapeutics, Inc. | 8 | $137 |
| Merck | 5 | $72 |
| Idorsia Pharmaceuticals US Inc | 4 | $55 |
| Supernus Pharmaceuticals, Inc. | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Eisai Inc. | 2 | $27 |
| Biogen | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 2 | $24 |
| Bausch Health US, LLC | 1 | $16 |
| Noven Therapeutics, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$242
How this compares
$9,028 in reported general payments places this provider in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 199 | $642,954 |
| VraylarCariprazine Hcl | 168 | $183,160 |
| CaplytaLumateperone Tosylate | 97 | $151,073 |
| RexultiBrexpiprazole | 108 | $138,102 |
| Invega TrinzaPaliperidone Palmitate | 13 | $116,536 |
| Abilify MaintenaAripiprazole | 37 | $101,318 |
| TrintellixVortioxetine Hydrobromide | 140 | $66,615 |
| Risperdal ConstaRisperidone Microspheres | 46 | $46,280 |
| AristadaAripiprazole Lauroxil | 14 | $40,575 |
| Lurasidone Hcl | 246 | $35,694 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $25,283 |
| Divalproex Sodium ErDivalproex Sodium | 209 | $21,092 |
| Aripiprazole | 168 | $14,827 |
| Paliperidone ErPaliperidone | 53 | $11,115 |
| QuviviqDaridorexant Hcl | 19 | $10,276 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza, Risperdal Consta | $695 | $805,771258 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,406 | $239,420145 claims |
| AbbVieVraylar | $600 | $183,160168 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,231 | $151,07397 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $280 | $66,615140 claims |
| Alkermes, Inc.Aristada, Lybalvi | $796 | $65,85830 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $55 | $10,27619 claims |
| MerckBelsomra | $72 | $5,35712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 404 psychiatric/mental health providers in Kansas.
Other psychiatric/mental health in Wichita
- Hayley KnappWichita$31K
- Deborah MurphyWichita$13K
- Julius QuinnWichita$10K
- Ashley MeluginWichita$9K
- Susan MilehamWichita$8K
- Angela TheobaldWichita$6K
- Alyson Taylor-SmithWichita$5K
- Ruth HartWichita$5K
- Julia McVayWichita$5K
- Amy AdamsWichita$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.